-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DKLew0TBBFBjxUwcTXdgXIxfMcul/JRHo7mVrOpwn4b+k/SEg3G+Gk2sRIdgMlFr qe7vgY/EjS14SI0WT/YrQg== 0000892569-03-002145.txt : 20030911 0000892569-03-002145.hdr.sgml : 20030911 20030911091134 ACCESSION NUMBER: 0000892569-03-002145 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20030911 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CIMA LABS INC CENTRAL INDEX KEY: 0000833298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411569769 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24424 FILM NUMBER: 03890973 BUSINESS ADDRESS: STREET 1: 10000 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344-9361 BUSINESS PHONE: 9529478700 MAIL ADDRESS: STREET 1: 10000 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344-9361 8-K 1 a93009e8vk.htm FORM 8-K CIMA Labs, Inc.
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

September 11, 2003

Date of report (Date of earliest event reported)

CIMA LABS INC.

(Exact Name of Registrant as Specified in its Charter)
         
Delaware   0-24424   41-1569769
 
 
(State of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)
     
10000 Valley View Road    
Eden Prairie, Minnesota   55344-9361
(Address of Principal Executive Offices)   (Zip Code)

(952) 947-8700

(Registrant’s Telephone Number, Including Area Code)

 

Item 5. Other Events.
Item 7(c). Exhibits.
SIGNATURES
Exhibit Index
EXHIBIT 99.1
EXHIBIT 99.2

Table of Contents

Item 5. Other Events.

     On September 11, 2003, CIMA LABS INC. issued a press release announcing that it had received a letter from Cephalon, Inc. regarding Cephalon’s earlier proposal to acquire all outstanding shares of CIMA common stock for $26.00 per share in cash. The press release and the Cephalon letter are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

Item 7(c). Exhibits.

     See Exhibit Index.

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 11, 2003

     
  CIMA LABS INC.
 
  By /s/  JAMES C. HAWLEY
   
    James C. Hawley
    Vice President, Chief Financial Officer and Secretary

 

Table of Contents

Exhibit Index

         
Exhibit No.   Description   Method of Filing
 
 
99.1   Press Release dated September 11, 2003.   Filed herewith
 
99.2   Letter to CIMA LABS INC. from Cephalon, Inc. dated as of September 10, 2003.   Filed herewith

  EX-99.1 3 a93009exv99w1.htm EXHIBIT 99.1 CIMA Labs, Inc.

 

EXHIBIT 99.1

CIMA LABS Receives Letter from Cephalon, Inc. Regarding Earlier Proposal

EDEN PRAIRIE, Minn. – September 11, 2003 – CIMA LABS INC. (NASDAQ: CIMA) today announced that it received a letter from Cephalon, Inc. (NASDAQ: CEPH) regarding Cephalon’s earlier proposal to acquire all outstanding shares of CIMA common stock for $26.00 per share in cash. The board of directors of CIMA will meet along with its advisors to consider this letter at a date that has yet to be determined. A copy of the letter has been filed with the U.S. Securities and Exchange Commission contemporaneously with this press release as an exhibit to CIMA’s Current Report on Form 8-K.

About CIMA LABS INC.

CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, orally disintegrating drug delivery technologies, OraSolv® and DuraSolv®. Based on these technologies, an active drug ingredient, which the company frequently taste-masks, is formulated into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. CIMA’s business involves a dual operating strategy. The company develops and manufactures orally disintegrating versions of drugs for pharmaceutical company partners for whom CIMA currently produces three branded prescription pharmaceuticals and three over-the-counter brands. CIMA is also developing proprietary products utilizing its orally disintegrating technologies, as well as its new OraVescent® enhanced absorption, transmucosal drug delivery technology.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations and beliefs of the management of CIMA and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this press release include statements about future financial and operating results of CIMA. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein.

In any forward-looking statement in which CIMA expresses an expectation or belief as to future results, that expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Risks and uncertainties pertaining to the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: CIMA’s successful completion of feasibility projects, consumer acceptance of CIMA’s products, the receipt of firm orders for CIMA’s products, the success of pharmaceutical companies in marketing CIMA’s products, production costs, production yields, agreeing to commercial terms with pharmaceutical companies for new collaborative development and license agreements, capacity utilization of product development and manufacturing resources,

 

 

the outcome of tests in humans of proposed products, returns on investments, and recognition of income tax benefits. Additional economic, business, competitive and/or regulatory factors affecting CIMA’s business generally that may cause actual results to differ materially are discussed in CIMA’s press releases and in its filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2002, especially in the Management’s Discussion and Analysis section, and its most recent Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K.

Additional Information and Where to Find It

Investors may access copies of the documents filed with the SEC by CIMA at the SEC’s website at www.sec.gov or on CIMA’s website at www.cimalabs.com. Free copies of CIMA’s SEC filings may also be obtained from CIMA at 10000 Valley View Road, Eden Prairie, Minnesota 55344 or by written request sent to the attention of “Chief Financial Officer” at the same address. CIMA does not undertake any obligation to (and expressly disclaims any such obligation to) update or alter their forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

         
    CIMA LABS INC.    
    James Hawley, 952/947-8700    
    jim.hawley@cimalabs.com    
    or    
    Sharon Merrill Associates, Inc.    
    Ehren Lister, 617/542-5300    
    elister@investorrelations.com    

Source: CIMA LABS INC.

  EX-99.2 4 a93009exv99w2.htm EXHIBIT 99.2 exv99w2

 

EXHIBIT 99.2

(CEPHALON LOGO)

September 10, 2003

Via telefax:  952-947-8711

Mr. Steven B. Ratoff
Chairman of the Board
CIMA Labs Inc.
10000 Valley View Road
Eden Prairie, MN 55344

Dear Steven:

     As we have discussed, we are disappointed with the CIMA Board’s decision not to negotiate with us with respect to our offer of $26.00 per share in cash. We continue to believe that our original proposal was “superior” to the current agreement with aaiPharma Inc.

     Our understanding of the aaiPharma merger agreement is that CIMA is permitted to engage in discussions or negotiations with us if the CIMA Board concludes in good faith that there is a “reasonable likelihood that [our proposal] would reasonably be expected to result in a Superior Proposal.” As I indicated to you when we last spoke, we also would consider modifying our proposal to allow CIMA shareholders to choose between cash, Cephalon stock, or a combination thereof. We remain flexible with our offer and strongly believe that we can negotiate a proposal that could result in a superior outcome for the CIMA shareholders.

     I strongly urge you and the CIMA Board of Directors to negotiate with us to that end. We are prepared to work with CIMA and its advisors to finalize an agreement expeditiously. I look forward to your response. Please contact me at 610-738-6103.

     
    Warmest regards,
     
     
    /s/ Frank Baldino, Jr
     
    Frank Baldino, Jr., Ph.D.
Chairman and Chief Executive Officer
     
FB    

      

      

      

Cephalon, Inc. • 145 Brandywine Parkway • West Chester, PA 19380-4245 • (610) 344-0200 • Fax (610) 344-0065

GRAPHIC 5 a93009a9300900.gif GRAPHIC begin 644 a93009a9300900.gif M1TE&.#EA`@$Z`/<``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``````@$Z```(_@#_"1SXSQ[!@@0-#E1XD*%" MA@(-^OLWT9]$A!/_WI$LS7K^K/ MH/@^'L77E6?7?V&CMFP)$:'*ARLA2O0HLNY!NAP]TOW(-V5&@37_$JP)Y9K0Z>F!0OE4G[BQ)5N33 MPXIA+TSX%B72FQE/+\8;F_?E@7Z!(^;;,K'=P;"IJF7Z>K-CFTC+!K5'-&S3 MLQ*+4CRK5*;LC\'__HFN2;;J]HEA*9M7_=JPW-D.V2HV^/"Q9(^;![:N.S'? M:86^:40<8,3MA9!QWJF$($LKJ454;'--!A9ST7U$760;1>8?8ZIM%U92&0&8 MD8'(]567?S)1UY5UKG78WW;B-00?0O05U8]/!&D7E7_V]$B?CT#V*)ES![7& MT7[>*512>`(6^-*3AS%)&T@KG;80B6M<9I2549.$# MEW:>O>B@>&HAV65&'T959VE_&=3*'GP.0D@A?/`QR"!][$''&U0D<8Q7%VUD M4#E*+.'%%5ZDH8:E:5":1J5[/.,C5%YM:9]($J'X&'6H]GA/C^NT2EU(_G/9 MHXY$ES%FH5@@V9K9<_?UQ\^//8H3#2VE^`+4AJ86]9-V7R$;YFK*>GBJ/:O6 M0ZT]R(C"2#QAU<H2#IE@2V2//'B)D`.\#",1K;\('W-N$.$INMAZ%=NT*6#[V1,-&"1FP M,(+!/]S"SCOVL&./+U2D8<]J(IWU(;FX\L5K<'E";V6%,;HH992L1\004AF50BBACS%@&4K6+=Q#++'.*4ZZU=:R180;6( MP$##9S_@P`/S.E#!(.KL@\\XK%Q3$78Y^>+!_@$?*-"`O8#_74$%4(1CC[6V MG?>4KLRVMJH]V8Q"B`D0L(W!`?"^2X4EFC0B!PL94/)J2::ZIM[B`FU6KM*M M&92&O1/4,(*]/I=1C;7585:01#_)8Y%DJ)Y7[MUJRC,(VQ!4SK;;J]CW&4=< M?JVK]"11!]UE<"TTBKT85+XVO@Q4@($6U_!3CS^UL'",M4OEM+(]U2@1_KT/ M,&"O_6JOP(Q.*EH'6G6,JQ-7RL$($21O7@=@01)TP`(?T&!M]CH``MS6B\:( M130>ZLZXU4N6J,$;%&FT\<['[UNQ<-**&.HZVC M&NK8'5/LH9WW86,/%H#B`P1WKQ#XPG!B*I=C2+*1ZE`+&VJ8'>`P``==P.-P MYHL'-#KQ`\!EX`35&!Y.ID>QI*2G5FA945=^M`YQZ$(#:OL;#+RQCM]%9C4_ M65E8?($J2P+E:L'[2DXL4H]U0*.$@'.`#L+1CU>!;3ZCA(ZC=.4HZCU&+PDA M1,(0A@'`50`-MWL03QY3CU\5)"2_L@A9WO&ZOXVQ8?:RP`ERT:,0WHU.-133 MX=11!Q9`8`&`*\(UK(6/D*QJ5?E`!@HL$$8EQ,-Z1E*,KLRB-%MV*3W/_G+' M*"JG/"U8BSY)^0I`[1&/\V!I64,:Y49:&15?9&!P]LK`(*RU'$R.:RD3*]XQBO$$7=>C3$PT$#DMX;8Q@? M$`)=/`0;$>)22824CW%\X0'09-L*?&&1_W"H1U2```,R<`AWT/0Q;IG-3H`3 MD\-MR38&45-U6NF)"?CL`!5(@SK,ER&,821H&P&*/3[)CZ+$0U=SY0Y'>U0+ M>X&S`C3HQ5T[^2L6)9),'Z(.5R*RGQY%1B%@,HBROAH12T"2`7_EJ2C0\2DL MB8,.J)Q`$7RQCG]J<1V[0"7@*H+0B7CNM0`AB8:U_ M#F5W]B`$O#H0BH*."B$AK.7OQ-3&D%K/1R7!*GW6$0<(G!`#%0!$)IL2UD_] M;I&[4PW_[#/+5EJD9)9X@`1\6`;#7<1]8HHOJ1([Q)Y()(2M9(I8VU0Z"TVB M7H!36Q'4@;M_P!8;?*A!Y0[P-P6P8!!`O2JK*C$"!_CL`6%L[2RL9^"ZK)%# M(8G&#^#5,`M@0!#B*&;JP"44?%A"7B@8AI`B@JK30*\[A'RLC86D480T$@C* M&]PJ#O?.]^6WJ5\J#ZKJ4*?%5)&R+@)- MW8QI>KX?G2XA]FB$_O("+(I^7'<>H MP1@#'()9%-1;IZ(M8^Y1"QY2+'[D**3;MF#%A:HP!2NH5ACTNB\'>VT M?''DD94ME*9!XZL(&M``"3@@!YPNLS(%VE0EGU>&[RLFKK69JAXMX0$*L)<. MC/'.L3Q665Y&=4%F^-Q4`;?7!6D(@]QM&'!3>`P0<``%*3 MN@)L_!-5ZZC$WR;XMT(';[G5^RBVZAQ@"[BA?(@SS8>:*XHQYB&+\>EREKM5 M2V!U1"?SL<>6:7P//D3P7G>X8Y`R(\\3/V_'P+NMJZZIV@,=WCA!%0PDD/H`!$'`` M:#8L``USP"#BX8[S_H,=OJB<,Q_@@0V3BU8;8>-$UO&%G2*``1X003/JT9J@ M'/EKES8Q(TP;Y\=!PQ)QH$2K;&2/+)/,'?*`KH]:E>6.]ZB5/3H&$!XP@&^' M(!0=;V6KQA$/<:@)5(0]DI$$)35""%P;1"[]/JR#K6-4HO.`%);#BG]D@1!K20(4X-..3 M/=9(FL/H@(9A(!(^PIB:)2CTHDNP^0L`=\,\_L"*NONC'NSXQS$6;*\&[!:V MT<,27D?!`?OA^0%W*/-LT+YL;`#B#L]`W%SOH0Y?B$(-!@-.=$`+V&`RO\`( M@\`'>Q`'>S`(>[`(T\`/V\`(6_`%8H`&<<`(QY![R;0.NN0WV:<$U5!DQQ`' M(\`"*R`"/T`+ZY!,G413QU`%D,0V+"`'OC!B#P!)**!".P%^<(($P!-/J,(]8`QU/(Z1==\7]FU``R@`&?C,V#@?RV0,&V&`'Z#`:MP;N)0`A/T=11`1>N`#'3P M`4B(5/;B`\U@5><39_(@#J70`F/D`#&P`D]4BP_0!>%09!EC`\!V``[@3_+` M7"5#"TK``20'!['P#+%P!1&%8B=G#XS``@43`AN```O@`!Y`">*P#6J`2L$F M;!!C$"%Q$O9@"3M5/R%008=#+53@B]:G`%_G-T3GC&V65+N4,%]G+U6G).!B M&"`M>@)F>!4<&Z_8`'9IS8^<`PG8Y`-@S8A0$6'9BWB MX`49H))3146`1@5$!VPD]UJLL@YR\'`50`FA9P_B(&@)XP!KQP^M@@P%\XNT M,"ORP`_BL`Y>H#8(XP!>@`WJH`0BX`4$LS8(4`%!&'Z*1C8E!$V;1F;L,'C- M9WU(A5D.L)!GPXKE5S\'P`#6]3?V$Y"H=AG#XRCVT`KR,G45H`1KM27'TA1* MQFN[(PYB@(4/0`%)@`Y6Y95(90$&4%R-1`4^V0!$MS9&P`JK@`IUV3``4`$U MH`[I8!#;0WUAB0[38`,9H`?'X'!RZ``=$`ED_O%/XQ`']2(!#6``ME-WX_`& MIG@`I!@#T;@R[Q`--;!+]F)H_Y!W_A`-7Y`!Z,D`06@/Z%`0V*"(]J($W?`I MZ_!K1:;@'+.`+]2`./Y!4,2!IE8!25!%"Q4JIM)I`!!M`)=1<.58!9"."3]F,$JR`*J^`%UE4!`X"T"P-M8GAZ9(BM>P0C[2"B>D M`&@%!^'0<=E@`V=SCV7@K315"QDP`7?&`"&P@7&V#E662G)G$.L0#].`2@W# M`M>@#GGW#N(P>./&`K7P.H(0+'V$,`^@!%G&,C^B9K[(`*'X./ZPF-9W_C;4 M-T;T:J<,(ZWCUF8-H#S0Q)G*PB)F,E#9,'BDF03>8$UMU1-F`3S1QACLP`80 M@``(0`$B$`L=QPZM\`%VR@!2P%GK\`N0)((`*O)0_LD%[45W+PD'O@APVK*(<^T`W6DG?(\)X(TV:A0%%DR;0@BP%N M,"L;L0YJ0'X/0#[GQ@_(D`$,\P`G,`S6<@_KD`XO$)D)TP5FD`%ND&+M2:R` M,P6?HA6K\F)KTP`9D`3YN'51\(YW9JE)E::JZDP,AI"]23_?LV$@QAY(5`_8 MX`)C5#GXD@6<)29'`1I*E$CG=5,ZQ0![0&`]_D(+),!/16`,]?`.#6=="Y"B M1&`R@*=/UA5!(5`-618-L\.G#I`!(V`!H0`/%L$.:>".UKB#=Y1WT&`"Y1>^ M@G!NXR`)71LO*.`I>6D!3CL,8C6!629<$AN,/Z_!T5NHNF%-T\`FI M:G.6!J"MT32C\5(!'1`+D!<6>D%>]8F,"C,X7``Q1L$E"\43I09`]S`.?&!= MIB@"^=>]OS`"R?,`*[`*[U0/XV`%+TL!@I!QUL(.S>DW#Q"A[D"U"X:>!G`" MAS`KU)(-+<"J!P`#_M#06^R@9L&FIIA;9.+@!#YI`1-4;CYBA$CUI`\``ISD M(S^H,`^`!J6%:NO@<&SVCB%@#!VW#E:`D"#K`$DP3MX+#2.`D/93`4`C1.GA M**,`+W@FP]E8OX-`ATMIIPOCBR!\-ACP`A[@!37@3)431A```KT@#XCC$RC2 M1DSQ#M#0`J[+6A\`"H@C5MIQ$V*R(?BP#LG`Q`T#!>N0=S^K`0E#`]0`?G.5 M#3<0F4+W`+U@$8!JQI:``!*PD$^@#NM@#H;@H8'9`P/:(^/0"$B8E5-PKW6' M#4*0E28%J@R;KR9EIQ*0N/'@'^-`!1*4?1E`!MH@,"5#C0AS`"N0;>\0_GIQ M`(<3Y`-`51#30`('4``#@%0^H`N;_`Z>@%3*DP&=@#@]X1;V4`N.6P/40%-9 M1@P3,$$/4``2A)!RZ*KW,@&CFP8E6)F8[`&A8`_0@!!;!5!=9`W4J#P/P`+Y MUUR>D1;_L[/!JDMO^`!>\'3C0`C?Y@`KD`OGM@ZUH`%@VC`T0$F?H@R4$]5/ M`'[L\)5%YSIT@:Y`B4`*#_J`$A("5F$P[Q-5X6*(3AJA- MQ;M:<=S.JS(2&946D4@4/3(*8%RY(D`%2O`"'T`#<-`+X9#`,+<'YWLO<,!" MNY/!K):?BU"DK6`"-JP]K`-,_#<<&W"O[(.8G!G M"<,`2C##==<*#68O1""$>:>LKGH`<2"(H(U*"2,"NN`.[[0.C-"T=JH`-3"T M/O*W@Y8O12`.QZ4]9&TOYEQFU,(("-!+\YK".VPO++`',@!.E&MA8?2)]S)D M7DW%:@ M`_D'J#WR"\JS2WJ@#N^T*@B]9K5]./<0#2P0+W\E"O702KV3#S<%D0[P`^9F MT$MP??4S!WU;=U=PL[TH`BID(^GQ$)^0W_:B`IRF6.(`@`>*=`L9FEN;V M.PDNU-B"4X$)`T@I$/40ZGT,LK_TK#YDSXHSP6<'Y7]1G7+AWLH`;@'8^S0B;9HR07+`_C M,'BJ>B^^\"OYI1%,UD;UP/$]?0??UTIJD@C@Q&;/Z%ZOT+2^70EW](CQ8`DB M&LD9H`OPR@Y?`$X*``$8T`6V+($GE(R54#6-%`-4*BG6.B.#@`'V08Y M&.N;:K,*"3PW@P<0"!XT>%`DG+M:?#S5>/#@P(,*7=2YXV=OW:\1#QV&6`7/ MWCA&L\HI:;#@`0,?XN*M:Y6&40:!#3'0LN>OICU[E30\6,``Q2IW..U!&^&@ MYP,):-3=M"=JP<,%%9)XNX@&F[U__OS]N_?/7BL(&B$PU)M>M_?#U\]KXGYR&#RP\U(.S M,6-^-OWQ6[>-R0,*_EBNE5/S$(+>65OMN;M'KM6'$-KJV1/78F!#..'B-2X7 M9T$#!@]TJ.-LS]*`L')7A*O9S]ZT$0TUYED73`:$/5,.A/W;11PZ=^V0[93[ M@`@T=^G4)%&U+3J#!0[VU#/7B@,@6A@4'+#P(&5%>_*1YY<6`L/`@U72\BJG MP!X(:P5C=L/I'<@&D@"#0<2QYPL:L+$IJW]"M*>6!AUT@*`-`!'JGWCR`7"/ MAP)XR(`N1A%!(`?(0J0A@BR8@$>(.@DJ1'[^<='(QK9:\)>&+$`@`P=$@,8P M$?O)9ZM[HEEB@0PH\1AJ`R:$,=&$MGW?&D>-)0?C!1YY:'A"H`0I"_@'P MG7QJB>XD#"@A[A]VTA#HH084:&.V$-:0IQR?OE@%GA^(>^A0=2II80NX+E&"2X/8(`%YK"ZIYPEY'3` M`2_.*4PQ=OA(+E,-L>+GG2]\94"$5[:1(X-.ZG%,27M(,3"FR&@0Q;+&V".Z"2U=Y)1@@',(B!.7_N(22O`QK`@!&([[DG M&Q9,,L`#+8BSMAP;-+CT`0=6H*6>#[]R<-`'_M`@I`$[Z+%'C0\4"-6#0M9A M60$HXFH(`1]B\2,#3>-!1NK`EGA)A%/JB4>3#R);`1O>O/B1+SB\J4<=Y[RJ M0C*3,DC#37X.MJ>*!BO@0`PS-H""N*T.#M$KL,K3J"&[M9'',)OL\86%1ED8 M\P$J6M`Y#8)N*_&!$'1I+JNNL#Q\+<7^X4<<5A!A*&`,?N#CD48>88010MBP M80+!8:E'GGQJ8N<8-3!P<*\?O+A"A`R("(4YA+T(M2$OL%G'ER7V1`&.6=#! MR:9?/G]`$$2;\R6FLA:PP`=>XJF(E<`J,`EGYGT0!)M>(5"ZH0_V`$>>E8G@ M>`0)@1=F82U^L$,4_GW;@S*P08L*9<`'E5B*/?!A#^>T0FH!TX$Q[%$DK+`C M"@TY404FL`)`7,."C-E*R+RR!HTPRB$6P`"4'F"#8\PF;Q>T!S88X1`J:*`! M#J@`+7J%`/4MH`"1Z=P#4("*#_DC=8?+6Y(.=T'.B"(*'HA,8""@/PQ@``Z0 M$(:U0M0/?^#C'\YAQ`3Z<[P')*$9$JH(H(`@$`-T+@,:<&-#5O`,]T$.3!;P M(NA.(0^\J7$=C8@!CR1`!G2L$82H>`$#`G.`"&3@#.AH2R>M'+T;P`R7X(`G5_J@' MWKR"CSW\(`E0\$(;*'&.S(C(,2*B1:%XM``#?)&$#Q"!%VZ1ELA9!'LB,(E` MEB""AYQH("<*3`,@T(`+V.DR:G3,O>Z5I+78HQZ^B`$*5I`!%'@,!2)8!8"F MR:\%(2(),5"F$NYP#A"&_0` M/7Y)L1['J(0>0K$SRQPI'M<(12>&H8M9&(,X^.!'.6:A"U\8XQB%.8R;L.&+ M81P#&N)PDY7.B!5UK$,9A%IO6D&GEJ^O@##^NJB^<(*.0)UL'/**JS\-0 M:4$6X=ELUA%%IV)E,Y0%E[[R61.(,06-:;F@M3(+6JU\4$D@,M)F@B>V2L3! M@Q^4K32QA5?9+L8?A@N0:H\TS;0NZ!@_>$`+)"B"2S9$"6GXP@;,\(QWL.4= MZ_!"@W[P`Q94H@9E\`+#6``%#&BA$'&@0@@8$3GL8N5@10K1=4&D))Y^"%'# MS6Z#/\A#!&=%,?FXQR@"PX`,9,`8UEKP@K!U.-6LI2OWNA(+P=4S:7KEMEEA M"XB4Q=/FWNNW6;EG_EK->)/-?(BQ:\&NBZW88"DB*;$I%I$]OE&#.+`@#D`8 MB`(((@A?C"(N/XB%/A<$OX%0@A5EH(4:OF,)"TR!%C_P13S6:P8-8&PK>4N, M&IV:F`)G5S%K/IRN],45S.+9QWC-BG3O@0T;P'$%W@C>87A\YQ$CALDX+UA*0LMFBH@,40F+H%A00TRH)$*V("_MK'E-:QH MKP8[^-3-K7.TK8U6'W.%%B,XC04RX`:>U7B-/*5GM5%MV34R^+(]=JZ(_B.< MUE83MW#1'NX]Q5U;:U_ZSOG.[H"MC15H9``":4"$"`IP`$)E."8>\,)6=04- M*DB-D/&!`+>$#0$-?/(.2^D*-&CQCZO8EM^8+9V(1UYM-6)EBHRQ!SOB$)@, M6Z`-X#*)913Y-!M^9*0?>]^%2A\;%\KS&,C[F&?'%,7$&R2OR#P` MKK1V`!EN_`]Q_$-!(/ZT"ZE8[GB_NN9Q?O4:0[\T-1@]2&B`#_[H`G M9KNK6*&Q!R5DH">8OI(N.^0A8SO:28]SY4&/^N036=RD=CX5!S]R%.N=;U)C M')=.XB`)B$`0"@KQ.K!!B3C@@`80"!GZ.L9IB`J@EQ79O/1+*_1+J\*SO*T8 MAT'(@/Z0FN"8@$_:`%%HP`8;,L5ROP:K/.3SP),+.A.T/*Q#$DS+.G-KC$IX M`.LC"&Y)EP=0``]@!=6JB7MXDUE[`!8X#63S`H:0#`50`GO8#@`M4*&B MNA*U^(8@`(+.Z1PSX"XRJ0`&B(-B.A(&;,#*>S]^ZSL]NXD61+?T"[+S&SE* MS$1+C+9[2\87O`=J`Y08Q+BRJ#@+B`H(>",,\`)$02AP804-4(#^T"/&.8`$ MQ`!1*"9F3+Y<=,!V.QQ62S%,1,84C$`PI$90VCLS(,&S! MDXM'=H1'%[Q'>$NCPQF'/4@#7_"!.&`$`:(!7]"$$8*"A@B!4#"=0BP$@;!` MLNBF#"@`","`"@A('6@"%]`AG`@'=@LK>U`'=H@'=Y"L>%@) MKY(LH3(CIQ1,S\RW-2RPX3*_SVS*2EM"P<1*9)73O.&RN?4Q>?,R-^\ HQ)&+&T1L-?/+%Y3DR.FR$C022;V,SKWDS:D,.M) -----END PRIVACY-ENHANCED MESSAGE-----